<div class="container">

<table style="width: 100%;"><tr>
<td>epileptic</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>Dose calibration of anti-epileptic drugs data</h2>

<h3>Description</h3>

<p>The SANAD (Standard and New Anti-epileptic Drugs) study (Marson
et al., 2007) is a randomized control trial of standard and new
anti-epileptic drugs, comparing effects on longer term clinical outcomes.
The data consists of longitudinal measurements of calibrated dose for the
groups randomized to a standard drug (CBZ) and a new drug (LTG). The
objective of the analysis is to investigate the effect of drug titration on
the relative effects of LTG and CBZ on treatment failure (withdrawal of the
randomized drug). There are several baseline covariates available, and also
data on the time to withdrawal from randomized drug.
</p>


<h3>Usage</h3>

<pre><code class="language-R">data(epileptic)
</code></pre>


<h3>Format</h3>

<p>This is a data frame in the unbalanced format, that is, with one row 
per observation. The data consists of columns for patient identifier, time 
of measurement, calibrated dose, baseline covariates, and survival data. 
The column names are identified as follows:
</p>

<dl>
<dt><code>id</code></dt>
<dd>
<p>integer: patient identifier.</p>
</dd>
<dt><code>dose</code></dt>
<dd>
<p>numeric: calibrated dose.</p>
</dd>
<dt><code>time</code></dt>
<dd>
<p>integer: timing of clinic visit at which dose recorded
(days).</p>
</dd>
<dt><code>with.time</code></dt>
<dd>
<p>integer: time of drug withdrawal/maximum follow up 
time (days).</p>
</dd>
<dt><code>with.status</code></dt>
<dd>
<p>censoring indicator (<code>1 = </code>withdrawal of 
randomized drug and <code>0 = </code>not withdrawn from randomized drug/lost to
follow up).</p>
</dd>
<dt><code>with.status2</code></dt>
<dd>
<p>censoring indicator (<code>1 = </code>withdrawal of 
randomized drug due to inadequate seizure control, (<code>2 = </code>withdrawal 
of randomized drug due to unacceptable adverse effects, and <code>0 = </code>not
withdrawn from randomized drug/lost to follow up).</p>
</dd>
<dt><code>with.status.uae</code></dt>
<dd>
<p><code>1 = </code>withdrawal due to unacceptable 
adverse effects, <code>0 = </code>otherwise.</p>
</dd>
<dt><code>with.status.isc</code></dt>
<dd>
<p><code>1 = </code>withdrawal due to inadequate 
seizure control, <code>0 = </code>otherwise.</p>
</dd>
<dt><code>treat</code></dt>
<dd>
<p>factor: randomized treatment (CBZ or LTG).</p>
</dd>
<dt><code>age</code></dt>
<dd>
<p>numeric: age of patient at randomization (years).</p>
</dd>
<dt><code>gender</code></dt>
<dd>
<p>factor: gender of patient. <code>F = </code>female, <code>M
  = </code>male.</p>
</dd>
<dt><code>learn.dis</code></dt>
<dd>
<p>factor: learning disability.</p>
</dd>
</dl>
<h3>Source</h3>

<p>SANAD Trial Group, University of Liverpool
</p>


<h3>References</h3>

<p>Marson AG, Appleton R, Baker GA, et al. A randomised controlled trial 
examining longer-term outcomes of standard versus new antiepileptic drugs. 
The SANAD Trial. <em>Health Tech Assess</em>. 2007; <strong>11(37)</strong>.
</p>
<p>Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness 
of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for 
treatment of partial epilepsy: an unblinded randomised controlled trial. 
<em>Lancet</em>. 2007; <strong>365</strong>: 2007-2013.
</p>
<p>Williamson PR, Kolamunnage-Dona R, Philipson P, Marson AG. Joint modelling of
longitudinal and competing risks data. <em>Stats Med.</em> 2008;
<strong>27(30)</strong>: 6426-6438.
</p>


<h3>See Also</h3>

<p><code>heart.valve</code>, <code>liver</code>, 
<code>mental</code>, <code>aids</code>.
</p>


</div>